This preclinical study demonstrates that shear-dependent vWF-platelet interactions correlate with ristocetin-dependent binding, providing mechanistic insights into thrombosis and potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
Does not support clinical translation of anti-vWF antibodies; leaves open their role in human shear-dependent thrombosis.
Under conditions of high shear stress, both hemostasis and thrombosis are initiated by the interaction of the platelet membrane glycoprotein (GP) Ib-IX-V complex with its adhesive ligand, von Willebrand factor (vWF), in the subendothelial matrix or plasma. This interaction involves the A1 domain of vWF and the N-terminal extracellular region of GP Ibalpha (His-1-Glu-282), and it can also be induced under static conditions by the modulators ristocetin and botrocetin. In this study, a panel of anti-vWF and anti-GP Ibalpha antibodies-previously characterized for their effects on ristocetin- and botrocetin-dependent vWF-GP Ib-IX-V interactions-was analyzed for their capacity to inhibit either the adhesion of Chinese hamster ovary cells expressing recombinant GP Ibalpha to surface-associated vWF under hydrodynamic flow or shear-stress-induced platelet aggregation. The combined results suggest that the shear-dependent interactions between vWF and GP Ibalpha closely correlate with ristocetin- rather than botrocetin-dependent binding under static conditions and that certain anti-vWF monoclonal antibodies are able to selectively inhibit shear-dependent platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: